10 likes | 126 Views
This supplementary figure shows the expression levels of Bcl-xL and Bax proteins in AsPC-1 cells treated with cisplatin and supplemented with rANX.II. Cells cultured with rANX.II and GST were treated with different cisplatin concentrations. Immunoblotting was used to analyze the protein levels, and the ratios of Bcl-xL to Bax were calculated. The results indicate the regulatory role of rANX.II in modulating Bcl-xL and Bax levels in response to cisplatin treatment.
E N D
Supplementary Fig. GST Addition rANX II Cisplatin(mM) 0 5 10 0 5 10 Bcl-xL Bax Actin GST 2.5 rANX II 2.0 1.5 Relatieve amount (Bcl-xL/Bax) 1.0 0.5 0 0 10 5 Cisplatin (mM) Supplementary Fig. Expression of Bcl-xL and Bax proteins following cisplatin treatment in rANX II-supplemented AsPC-1 cells. AsPC-1 cells were cultured in the presence of rANX II (0.8 µg/mL) and GST (0.027 µg/mL) for 24 h, and then treated with cisplatin at the indicated concentration. Whole cell lysates were prepared, and the expression levels of Bcl-xL, Bax, and actin proteins were analyzed by immunoblotting as described in Materials and Methods. Results depicted in the figure are representative of findings from three independent experiments. Protein levels of Bcl-xL and Bax were normalized to actin levels, and ratios of Bcl-xL to Bax levels are presented as relative values to those of control cells without cisplatin treatment (GST alone). Data are presented as mean ± SD.